

CORRECTION

Correction to: Budget Impact Analysis of Brivaracetam Adjunctive Therapy for Partial-Onset Epileptic Seizures in Valencia Community, Spain

Isabel Barrachina-Martínez¹  · David Vivas-Consuelo¹  · Anna Piera-Balbastre²

Published online: 20 February 2018
© Springer International Publishing AG, part of Springer Nature 2018

Correction to: Clin Drug Investig
<https://doi.org/10.1007/s40261-017-0615-z>

In the original publication, the abstract, conclusion was incorrectly published.

Abstract, Conclusions which previously read:

Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy when used as monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.

Should read:

Brivaracetam is a therapeutic alternative that allows savings for the health system in patients with non-controlled epilepsy in monotherapy, having a fixed, predictable annual cost (independent of dose) from the first day of treatment as the lack of need for titration means the patient is within a range of therapeutic doses from the first dose.

The original article was corrected.

The original article can be found online at <https://doi.org/10.1007/s40261-017-0615-z>.

✉ Isabel Barrachina-Martínez
ibarrach@upvnet.upv.es

¹ Department of Economics and Social Sciences, Research Centre for Health Economics and Management, INECO, Universitat Politècnica de València, Edificio 7 J, Camino de Vera s/n, 46022 Valencia, Spain

² Department of Neurology, Hospital Clínico Universitario de Valencia, Valencia, Spain